omalizumab chronic urticaria
Selected indexed studies
- Chronic Spontaneous Urticaria: A Review. (JAMA, 2024) [PMID:39325444]
- Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. (Clin Rev Allergy Immunol, 2020) [PMID:32418171]
- Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. (J Allergy Clin Immunol, 2024) [PMID:38431226]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. (2020) pubmed
- Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis. (2024) pubmed
- Chronic Spontaneous Urticaria: A Review. (2024) pubmed
- Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. (2017) pubmed
- Omalizumab in chronic urticaria. (2012) pubmed
- New insights into chronic inducible urticaria. (2024) pubmed
- Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. (2024) pubmed
- Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. (2024) pubmed
- Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. (2023) pubmed
- Management of chronic urticaria: Treatment options when omalizumab fails. (2025) pubmed